Terasawa Teruhiko, Nishida Hiroshi, Kato Katsuaki, Miyashiro Isao, Yoshikawa Takaki, Takaku Reo, Hamashima Chisato
Section of General Internal Medicine, Department of Emergency and General Internal Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; Center for Clinical Evidence Synthesis, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, United States of America.
Department of Health Information and Statistics, Panasonic Health Care Center, Osaka, Japan.
PLoS One. 2014 Oct 14;9(10):e109783. doi: 10.1371/journal.pone.0109783. eCollection 2014.
To identify high-risk groups for gastric cancer in presumptively healthy populations, several studies have investigated the predictive ability of the pepsinogen test, H. Pylori antibodies, and a risk-prediction model based on these two tests. To investigate whether these tests accurately predict gastric cancer development, we conducted a systematic review and meta-analysis.
PubMed and other electronic databases were searched for cohort studies published in English or Japanese from January 1985 through December 2013. Six reviewers identified eligible studies, and at least two investigators extracted data on population and study-design characteristics, quality items, and outcomes of interest. Meta-analyses were performed on non-overlapping studies.
Nine prospective cohorts from Eastern Asia reported in 12 publications, including 33,741 asymptomatic middle-aged participants of gastric cancer screening, were eligible. For discriminating between asymptomatic adults at high and low risk of gastric cancer, the pepsinogen test (summary hazard ratio [HR], 3.5; 95% confidence interval [CI], 2.7-4.7; I2 = 0%) and H. pylori antibodies (summary HR, 3.2; 95% CI, 2.0-5.2; I2 = 0%) were statistically significant predictors as standalone tests. Although the risk-prediction model was in general moderately accurate in separating asymptomatic adults into four risk groups (summary c-statistic, 0.71; 95% CI: 0.68-0.73; I2 = 7%), calibration seemed to be poor. The study validity was generally limited.
The serum pepsinogen test, H. pylori antibodies, and the four-risk-group model for predicting gastric cancer development seem to have the potential to stratify middle-aged presumptively healthy adults. Future research needs to focus on comparative studies to evaluate the impact of screening programs adopting these tests. Also, validation, preferably with model updating, is necessary to see whether the current model performance is transferable to different populations.
为了在假定健康的人群中识别胃癌高危群体,多项研究调查了胃蛋白酶原检测、幽门螺杆菌抗体以及基于这两项检测的风险预测模型的预测能力。为了研究这些检测能否准确预测胃癌的发生,我们进行了一项系统评价和荟萃分析。
检索PubMed及其他电子数据库,查找1985年1月至2013年12月期间以英文或日文发表的队列研究。6名评审员确定符合条件的研究,至少两名研究人员提取有关人群和研究设计特征、质量项目以及感兴趣结局的数据。对不重叠的研究进行荟萃分析。
东亚地区的9项前瞻性队列研究发表于12篇文献中,包括33741名无症状中年胃癌筛查参与者,符合条件。对于区分胃癌高危和低危的无症状成年人,胃蛋白酶原检测(汇总风险比[HR],3.5;95%置信区间[CI],2.7 - 4.7;I² = 0%)和幽门螺杆菌抗体(汇总HR,3.2;95% CI,2.0 - 5.2;I² = 0%)作为独立检测具有统计学意义的预测指标。尽管风险预测模型在将无症状成年人分为四个风险组方面总体上具有中等准确性(汇总c统计量,0.71;95% CI:0.68 - 0.73;I² = 7%),但校准似乎较差。研究的有效性总体上有限。
血清胃蛋白酶原检测、幽门螺杆菌抗体以及预测胃癌发生的四风险组模型似乎有潜力对假定健康的中年成年人进行分层。未来的研究需要聚焦于比较研究,以评估采用这些检测的筛查项目的影响。此外,有必要进行验证,最好是更新模型,以确定当前模型的性能是否可转移到不同人群。